Market Analysis of Omeprazole Industry in China 2016-2021

  • ID: 3987675
  • Report
  • Region: China
  • 67 pages
  • ASKCI Consulting Co., Ltd
1 of 4

In 2015, sales volume of omeprazole in China was 12.9 tonnes and sales value was RMB one billion, with YoY growth of 5% and 5.2%. In the coming years, with the increase of patients suffering from digestive disease, their need for omeprazole is increasing. Meanwhile, the number of hospitals in the 13th five-year plan period will go up, as will their input of omeprazole. It is predicted that, in 2021, sales value of omeprazole in China will reach RMB1.37 billion.

As the coverage of related policies is expanding, essential medicines with good quality and low prices will be the first choice for basic medical institutions. Moreover, people’s medical consciousness increases, insurance institutions lead people to the right direction. The asymmetric phenomenon between consumers and doctors and pharmaceutical enterprises will be improved. There will be more choices of medicines for patients, which will increase sales amount for omeprazole. Under these circumstances, sales of omeprazole tends to grow.



Please note that this report takes 1-2 business days for delivery.
Note: Product cover images may vary from those shown
2 of 4

1 Overview of China Omeprazole Industry
1.1 General Situation
1.2 Status of China Chemical Drugs Industry, 2011-2015

2 Sales Analysis of Omeprazole in China in 2015
2.1 Overview
2.2 Sales by Specifications
2.3 Sales in Major Cities
2.3.1 Shanghai
2.3.2 Beijing
2.3.3 Guangzhou
2.3.4 Zhengzhou
2.3.5 Hangzhou
2.3.6 Tianjin
2.3.7 Jinan
2.3.8 Chongqing
2.3.9 Chengdu
2.3.10 Nanjing

3 Competition Analysis of Major Companies of Omeprazole in China
3.1 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
3.1.1 Development Analysis
3.1.2 Major Products
3.1.3 Operation Analysis
3.1.4 Competition Advantages
3.1.5 Development Strategy
3.2 Changzhou Siyao Pharmaceutical Co., Ltd.
3.3 AstraZeneca
3.4 Hunan Dinuo Pharmaceutical Co., Ltd.
3.5 Guilin Hwasun Pharmaceutical Co., Ltd.
3.6 Guizhou Warmen Pharmaceutical Co. Ltd.
3.7 Jiangsu Wuzhong Pharmaceutical Group Corporation
3.8 Jinzhou Jiutai Pharmaceutical
3.9 Guangdong Eashu Pharmaceutical Co., Ltd.

4 Prospect of China Omeprazole Industry, 2016-2021

5. Analysis of Investment and Financing Strategy Plan of Omeprazole Enterprises
5.1 Background and Meaning of Development Strategy Plan of Omeprazole Enterprises
5.1.1 Need for Enterprises’ Transformation and Upgrading
5.1.2 Need for Larger and Stronger Enterprises
5.1.3 Need for Sustainable Development
5.2 The Basis for the Omeprazole Enterprise Strategy Planning
5.2.1 Industrial Policies in China
5.2.2 Law of Industry Development
5.2.3 Resources and Capacity of Enterprises
5.2.4 Predictable Strategic Positioning
5.3 The Strategy Analysis of the Omeprazole Enterprise Strategy Planning
5.3.1 Comprehensive Strategy Planning
5.3.2 Technical Development Strategies
5.3.3 Regional Strategy Planning
5.3.4. Industrial Strategy Planning
5.3.5 Brand Marketing Strategies
5.3.6 Competitive strategy Planning
5.4 Implementation of Key Customer Strategies in the Electronic Manufacturing Services Market
5.4.1 Necessity for the Implementation of Key Customer Strategies
5.4.2 Authentication and Confirmation of VIPs of Enterprises
5.4.3 Exploitation and Cultivation of VIPs
5.4.4 Issues to be Solved during Implementation of Key Customer Strategies
5.4.3 Analysis of Marketing Strategy of Key Clients

List of Figures

Figure 1 Numbers of China chemical drugs enterprises, 2011-2015
Figure 2 Total assets of China chemical drugs enterprises, 2011-2015
Figure 3 Sales revenues of China chemical drugs industry, 2011-2015
Figure 4 Total profits of China chemical drugs industry, 2011-2015
Figure 5  Asset-liability ratios of China chemical drugs industry, 2011-2015
Figure 6 Rates of profits to cost and expense of China chemical drugs industry, 2011-2015
Figure 7 Rates of income as a percentage of sales of China chemical drugs industry, 2011-2015
Figure 8 Rates of return on total assets of China chemical drugs industry, 2011-2015
Figure 9 Gross profit margins of China chemical drugs industry, 2011-2015
Figure 10 Receivables turnovers of China chemical drugs industry, 2011-2015
Figure 11 Liquidity turnovers of China chemical drugs industry, 2011-2015
Figure 12 Turnovers of total assets of China chemical drugs industry, 2011-2015
Figure 13 Costs of sales of China chemical drugs industry, 2011-2015
Figure 14 Sales expenses of China chemical drugs industry, 2011-2015
Figure 15 Management expenses of China chemical drugs industry, 2011-2015
Figure 16 Financial expenses of China chemical drugs industry, 2011-2015
Figure 17 Output of China chemical drugs industry, 2011-2015
Figure 18 Sales volume of China omeprazole industry, 2011 -2015
Figure 19 Sales value of China omeprazole industry, 2011-2015
Figure 20 Markets shares of key enterprises in China omeprazole industry in 2015
Figure 21 Markets shares of key enterprises in China omeprazole industry in 2015
Figure 22 Sales structure of China omeprazole industry by specifications in 2015
Figure 23 Sales value structure of China omeprazole products of different packages in 2015
Figure 24 Sales volume structure of China omeprazole of different packages in 2015
Figure 25 Sales value structure of China omeprazole products of different packages in 2015
Figure 26 Sales volume of omeprazole in Shanghai, 2011-2015
Figure 27 Sales value of omeprazole in Shanghai, 2011-2015
Figure 28 Sales forecast of omeprazole in Shanghai, 2016-2021
Figure 29 Sales volume of omeprazole in Beijing, 2011-2015
Figure 30 Sales value of omeprazole in Beijing, 2011-2015
Figure 31 Sales forecast of omeprazole in Beijing, 2016-2021
Figure 32 Sales volume of omeprazole in Beijing, 2011-2015
Figure 33 Sales value of omeprazole in Guangzhou, 2011-2015
Figure 34 Sales forecast of omeprazole in Guangzhou, 2016-2021
Figure 35 Sales volume of omeprazole in Zhengzhou, 2011-2015
Figure 36 Sales value of omeprazole in Zhengzhou, 2011-2015
Figure 37 Sales forecast of omeprazole in Zhengzhou, 2016-2021
Figure 38 Sales volume of omeprazole in Hangzhou, 2011-2015
Figure 39 Sales value of omeprazole in Hangzhou, 2011-2015
Figure 40 Sales forecast of omeprazole in Hangzhou, 2016-2021
Figure 41 Sales volume of omeprazole in Tianjin, 2011-2015
Figure 42 Sales value of omeprazole in Tianjin, 2011-2016
Figure 43 Sales forecast of omeprazole in Tianjin, 2016-2021
Figure 44 Sales volume of omeprazole in Jinan, 2011-2015
Figure 45 Sales value of omeprazole in Jinan, 2011-2015
Figure 46 Sales forecast of omeprazole in Jinan, 2016-2021
Figure 47 Sales volume of omeprazole in Chongqing, 2011-2015
Figure 48 Sales value of omeprazole in Chongqing, 2011-2015
Figure 49 Sales forecast of omeprazole in Chongqing, 2016-2021
Figure 50 Sales volume of omeprazole in Chengdu, 2011-2015
Figure 51 Sales value of omeprazole in Chengdu, 2011-2015
Figure 52 Sales forecast of omeprazole in Chengdu, 2016-2021
Figure 53 Sales volume of omeprazole in Nanjing, 2011-2015
Figure 54 Sales value of omeprazole in Nanjing, 2011-2015
Figure 55 Sales forecast of omeprazole in Nanjing, 2016-2021
Figure 56 Sales volume forecast of China omeprazole, 2016-2021
Figure 57 Sales value forecast of China omeprazole, 2016-2021

List of Tables

Table 1 Economic indicators of China chemical drugs industry, 2013-2015
Table 2 Total assets of China chemical drugs enterprises, 2011-2015
Table 3 Sales revenues of China chemical drugs industry, 2011-2015
Table 4 Total profits of China chemical drugs industry, 2011-2015
Table 5 Costs of sales of China chemical drugs industry, 2011-2015
Table 6 Sales expenses of China chemical drugs industry, 2011-2015
Table 7 Management expenses of China chemical drugs industry, 2011-2015
Table 8 Financial expenses of China chemical drugs industry, 2011-2015
Table 9 omeprazole enterprises in China
Table 10 Sales by regions in China omeprazole industry in 2015
Table 11 Sales volume of omeprazole by specifications in 2015
Table 12 Sales value of omeprazole by specifications in 2015
Table 13 Sales volume of omeprazole of different packages in 2015
Table 14 Sales value of China omeprazole products of different packages in 2015
Table 15 Numbers of hospitals in Shanghai, 2011-2015
Table 16 Numbers of hospitals in Beijing, 2011-2015
Table 17 Numbers of hospitals in Guangzhou, 2011-2015
Table 18 Numbers of hospitals in Zhengzhou, 2011-2015
Table 19 Numbers of hospitals in Hangzhou, 2011-2015
Table 20 Numbers of hospitals in Tianjin, 2011-2015
Table 21 Numbers of hospitals in Jinan, 2011-2015
Table 22 Numbers of hospitals in Chongqing, 2011-2015
Table 23 Numbers of hospitals in Chengdu, 2011-2015
Table 24 Omeprazole products of Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Table 25 Sales revenues and total profits of Jiangsu Aosaikang Pharmaceutical Co., Ltd., 2012-2014
Table 26 Rates of sales profits and gross profits of Jiangsu Aosaikang Pharmaceutical Co., Ltd., 2012-2014
Table 27 Competition advantages of Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Table 28 Omeprazole products of Changzhou Siyao Pharmaceutical Co., Ltd.
Table 29 Sales revenues and total profits of Changzhou Siyao Pharmaceutical Co., Ltd., 2012-2014
Table 30 Sales profit rates and gross profit rates of Changzhou Siyao Pharmaceutical Co., Ltd., 2012-2014
Table 31 Competition advantages of Changzhou Siyao Pharmaceutical Co., Ltd.
Table 32 Development strategy of Changzhou Siyao Pharmaceutical Co., Ltd.
Table 33 Omeprazole products of AstraZeneca
Table 34 Sales revenues and total profits of Wuxi supply base, 2012-2014
Table 35 Sales profit rates and gross profit rates of Wuxi supply base, 2012-2014
Table 36 Competition advantages of AstraZeneca
Table 37 Sales revenues and total profits of Hunan Dinuo Pharmaceutical Co., Ltd., 2012-2014
Table 38 Sales profit rates and gross profit rates of Hunan Dinuo Pharmaceutical Co., Ltd., 2012-2014
Table 39 Omeprazole products of Guilin Hwasun Pharmaceutical Co., Ltd.
Table 40 Sales revenues and total profits of Guilin Hwasun Pharmaceutical Co., Ltd., 2012-2014
Table 41 Sales profit rates and gross profit rates of Guilin Hwasun Pharmaceutical Co., Ltd., 2012-2014
Table 42 Competition advantages of Guilin Hwasun Pharmaceutical Co., Ltd.
Table 43 Omeprazole product of Guizhou Warmen Pharmaceutical Co. Ltd.
Table 44 Sales revenues and total profits of Guizhou Warmen Pharmaceutical Co. Ltd., 2013-2015
Table 45 Competition advantages of Guizhou Warmen Pharmaceutical Co. Ltd.
Table 46 Total assets and total liabilities of Jiangsu Wuzhong Pharmaceutical Group Corporation, 2014-2015
Table 47 Asset-liability ratios and profitability index of Jiangsu Wuzhong Pharmaceutical Group Corporation, 2014-2015
Table 48 Competition advantages of Jiangsu Wuzhong Pharmaceutical Group Corporation
Table 49 Omeprazole products of Jinzhou Jiutai Pharmaceutical
Table 50 Sales revenues and total profits of Jinzhou Jiutai Pharmaceutical, 2012-2014
Table 51 Sales profit rates and gross profit rates of Jinzhou Jiutai Pharmaceutical, 2012-2014
Table 52 Competition advantages of Jinzhou Jiutai Pharmaceutical
Table 53 Revenues and total profits of Guangdong Eashu Pharmaceutical Co., Ltd., 2013-2015
Table 54 Competition advantages of Guangdong Eashu Pharmaceutical Co., Ltd.

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca
  • Changzhou Siyao Pharmaceutical Co., Ltd.
  • Guangdong Eashu Pharmaceutical Co., Ltd.
  • Guilin Hwasun Pharmaceutical Co., Ltd.
  • Guizhou Warmen Pharmaceutical Co. Ltd.
  • Hunan Dinuo Pharmaceutical Co., Ltd.
  • Jiangsu Wuzhong Pharmaceutical Group Corporation
  • Jinzhou Jiutai Pharmaceutical
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll